Proteomics International Laboratories (ASX:PIQ) received a dedicated billing code from the American Medical Association for its PromarkerD diagnostic test, which identifies kidney function decline in patients with Type 2 diabetes, according to a Thursday filing with the Australian bourse.
The new code will take effect for insurance claims from Oct. 1, the filing said.
The company also submitted a pricing recommendation for the test to the Centers for Medicare and Medicaid Services (CMS), the filing added.
Preliminary pricing for the test is expected in September following a review by CMS's advisory panel, the company said.